Sensei Biotherapeutics Inc (SNSE)
NASDAQ (CM) NASDAQ (CM) Primary Summary
What Makes Sensei Biotherapeutics (SNSE) a New Buy Stock
Sensei Biotherapeutics (SNSE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Why Is Sensei Biotherapeutics (SNSE) Stock Down 40% Today?
Sensei Biotherapeutics (NASDAQ: SNSE ) stock is falling on Friday after it failed to impress investors with its latest Phase 1/2 clinical trial data for SNS-101. SNS-101 is a human monoclonal antibody targeting the immune checkpoint VISTA.
Sensei Biotherapeutics Inc Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| KR Kevin Roan Stempoint Capita LLP | 132,873 | $4.19M | $1.56M | -$2.62M | -62.66% |
| OM Olga Maltseva Catalio Capital Management LP | 14,718 | $126,280 | $173,230.86 | $46,950.86 | 37.18% |
Sensei Biotherapeutics Inc (SNSE) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Sensei Biotherapeutics Inc ever had a stock split?
Sensei Biotherapeutics Inc Profile
| Biotechnology Industry | Healthcare Sector | Christopher W. Gerry CEO | NASDAQ (CM) Exchange | 81728A207 CUSIP |
| US Country | 14 Employees | - Last Dividend | 17 Jun 2025 Last Split | 4 Feb 2021 IPO Date |
Overview
Sensei Biotherapeutics, Inc. is a pioneering immuno-oncology company focused on the discovery and development of novel therapeutics for cancer patients. Leveraging its Tumor Microenvironment Activated Biologics platform, the company aims to create treatments that selectively modulate the tumor microenvironment to enhance the body's immune response to cancer. Originally founded as Panacea Pharmaceuticals, Inc., Sensei Biotherapeutics has grown since its inception in 1999 to become a leader in the field of cancer immunotherapy. With its headquarters located in Rockville, Maryland, the company continues to forge partnerships, such as with The University of Washington, to advance its research and development efforts towards clinical applications.
Products and Services
Sensei Biotherapeutics’ product pipeline showcases a range of innovative therapeutics designed to empower the immune system in the fight against solid tumors. Each candidate embodies the company's dedication to selectively targeting key mechanisms within the tumor microenvironment:
- SNS-101: A clinical Phase 1/2 active monoclonal antibody targeting the immune checkpoint VISTA. This investigational treatment represents a novel approach to inhibiting a pathway thought to contribute to the immune system's inability to combat cancer effectively.
- SNS-103 and SNS-102: Both compounds are in the early stages of development. These active monoclonal antibodies are being explored for their potential to treat solid tumors by selectively modulating the tumor microenvironment to elicit a stronger immune response against cancer cells.
- SNS-201: A bispecific antibody that targets CD28, showcasing Sensei Biotherapeutics’ effort to innovate in the space of immune modulation. By engaging with CD28, SNS-201 aims to amplify the activation of T cells, a critical component of the immune system, against cancer cells.
